Hamlet BioPharma Stock

Hamlet BioPharma EBITDA per Employee

The EBITDA per Employee of Hamlet BioPharma (HAMLET B.SL) as of Aug 12, 2026 is -5.58 M SEK. In the previous year, EBITDA per Employee was -4.12 M SEK — a change of 35.63% (lower).

EBITDA per Employee

-5.58 MSEK

YoY

35.63%

Last updated:

EBITDA per Employee of Hamlet BioPharma is 2026 -5.58 M SEK. EBITDA per Employee of Hamlet BioPharma was 2025 -4.12 M SEK. It decreases by 35.63% lower compared to the previous year.
Access this data via the Eulerpool API
Get Free API Key

Hamlet BioPharma Stock analysis

What does Hamlet BioPharma do? Hamlet BioPharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Hamlet BioPharma stock

EBITDA per Employee of Hamlet BioPharma is -5.58 M SEK in 2026.

EBITDA per Employee of Hamlet BioPharma changed from -4.12 M SEK to -5.58 M SEK, representing a 35.63% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Employee Hamlet BioPharma since 2006 – with annual values, charts, and detailed analysis.

EBITDA per employee measures operating cash earnings generated per employee, showing workforce productivity before depreciation and financing effects.

EBITDA per Employee's SEK is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA per Employee's Hamlet BioPharma historically and in real time.

Access this data via the Eulerpool API
Get Free API Key

Workforce — Hamlet BioPharma

EmployeesRevenue per EmployeeProfit per EmployeeMarket Cap per EmployeeEBIT per EmployeeEBITDA per EmployeeR&D per EmployeePP&E per Employee

All Key Metrics — Hamlet BioPharma